MEDIORG Medicamen Organics Q4 FY25 results (Jan–Mar 2025) and concall
Medicamen Organics Limited reported robust financial performance in FY25 with significant revenue and PAT growth, driven by strategic global expansion and diversification into new segments like cosmetics. The company is investing in capacity expansion in Haridwar and a new facility in Nepal to support future demand. While facing challenges with high debtor days, management is focused on improving working capital efficiency and achieving ambitious growth and margin targets for the coming years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 |
|---|---|---|---|---|
| Revenue | 11 | 14 | 17 | 20 |
| EBITDA | 2 | 2 | 3 | 3 |
| Net profit | 1 | 1 | 2 | 2 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
